UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
: November 23, 2009
iBASIS, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE
|
|
000-27127
|
|
04-3332534
|
(State or Other
Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
20
Second Avenue, Burlington, MA
|
|
01803
|
(Address of
Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(781) 505-7500
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item
1.01
Entry into a Material Definitive Agreement.
On November 23, 2009, iBasis, Inc.
(the Company) entered into a Settlement Agreement (the Settlement Agreement)
with KPN B.V. (Purchaser), Koninklijke KPN N.V. (KPN) and Celtic
ICS Inc. (Merger Sub). The
Settlement Agreement addresses certain matters
concerning the tender offer by Purchaser, which is a wholly owned subsidiary of
KPN, pursuant to which Purchaser has offered to buy all outstanding shares of
the Companys common stock, par value $0.001 per share (Shares) that it does
not already own for the Offer Price (as defined below), upon the terms and
subject to the conditions set forth in the offer to purchase dated July 28,
2009 (the Offer to Purchase) and the related letter of transmittal (which,
together with any amendments or supplements thereto, collectively constitute
the Offer). The Offer is described in a Tender Offer Statement and Rule 13e-3
Transaction Statement filed by KPN and Purchaser under cover of
Schedule TO (together with exhibits, as amended, the Schedule TO) with
the Securities and Exchange Commission (the SEC) on July 28, 2009.
The
following is a summary of the material provisions of the Settlement Agreement
and is qualified in its entirety by reference to the full text of the
Settlement Agreement, a copy of which is filed as
Exhibit 10.1 to this Current Report on Form 8-K
and is incorporated herein by reference.
This summary of terms has been included in this Current Report on Form 8-K
to provide you with information regarding the terms of the
Settlement Agreement and is not intended to modify or supplement any
factual disclosures about the Company, KPN, Purchaser or Merger Sub (or their
affiliates) in public reports filed with the SEC. In particular, the Settlement Agreement and
this summary of terms are not intended to be, and should not be relied upon as,
disclosures regarding any facts and circumstances relating to the Company, KPN,
Purchaser or Merger Sub (or their affiliates).
Dismissal of Litigation and Mutual Releases.
Pursuant to the terms of the Settlement Agreement, substantially
concurrently with the execution and delivery of the Settlement Agreement,
counsel to KPN, the Company and the special committee, on behalf of their
respective clients, entered into, and on November 23, 2009 will file with
the Delaware Court of Chancery and the United States District Court for
the Southern District of New York,
stipulations in the litigation entitled iBasis, Inc. v. Koninklijke
KPN N.V., et al., Civil Action No. 09-7288 (AKH), pending in the
United States District Court for the Southern District of New York (the Delaware Litigation) and the
litigation entitled iBasis, Inc. v. Koninklijke KPN N.V., et al.,;
KPN B.V. and Koninklijke KPN N.V. v. IBasis, Inc., et al., Civil
Action No. 4774-VCS, pending in the Chancery Court of the State of
Delaware (the New York Federal
Litigation) dismissing with prejudice the respective claims of each of the
parties in those proceedings.
In addition, the Settlement
Agreement provides that KPN, Purchaser, Merger Sub and the Company, on behalf
of themselves and each of their affiliates, directors, officers, employees,
successors, agents, representatives and assigns, release each other from all
existing and future claims arising out of or that are directly related to the
allegations made in the Delaware Litigation or the New York Federal Litigation.
Termination of Rights
Agreement.
Pursuant to the terms of the
Settlement Agreement, the Company will
terminate the Rights Agreement (as defined in Item 1.02 below) within four
business days of the date of the Settlement Agreement.
The Offer
.
The Settlement Agreement requires
KPN, Purchaser and Merger Sub to amend the Offer to increase the purchase price
to $3.00 per Share, net to the seller in cash, without interest and less required
withholding taxes (the Offer Price), to provide that the
conditions will be as set forth in Conditions to the Offer below and
not others, to provide that the expiration date is December 8, 2009
and to otherwise conform to the requirements of the Settlement Agreement. KPN, Purchaser and Merger Sub expressly
reserve the right to waive any of the conditions to the Offer and to make any
other changes in the terms of or conditions to the Offer;
provided
that KPN, Purchaser and Merger
Sub may not (i) reduce the amount of, or change the form of, the
consideration to be paid in the Offer or reduce the number of Shares sought in
the Offer, (ii) amend or waive satisfaction of the Majority-of
the-Minority Condition, which condition requires
there being validly tendered and not withdrawn prior to the expiration of the
Offer a number of Shares representing at least a majority of the Shares
outstanding immediately prior to the expiration of the Offer, excluding Shares
owned by Purchaser, KPN, Merger Sub or any of their respective affiliates or
any director or officer of Purchaser, KPN, Merger Sub or the Company,
impose additional conditions to the Offer, amend, modify, supplement, or
otherwise change any of the conditions to the Offer set forth in Conditions
to the Offer below, (iii) amend any other term of the Offer in any manner
adverse to the stockholders of the Company (other than KPN and its affiliates)
or that would reasonably be expected to, individually or in the aggregate,
prevent, materially delay or materially impede the consummation of the Offer or
(iv) extend the expiration date of the Offer except as otherwise provided
in the Settlement Agreement. In
addition, the Majority-of-the-Majority Condition is nonwaivable.
Extensions of the Offer
.
KPN, Purchaser and Merger Sub may
extend the Offer for two successive periods not to exceed 10 business days
each, until the conditions to the Offer are satisfied or waived if any of the
conditions is not
2
satisfied or
waived on any scheduled expiration date of the Offer. In no event will Purchaser be required or
permitted to extend the Offer beyond January 8, 2010. The Settlement Agreement obligates Purchaser to
extend the Offer (but not beyond January 8, 2010) for a period required by
any rule, regulation, interpretation or position of the SEC or the staff
thereof applicable to the Offer or any period otherwise required by applicable
law.
The Settlement
Agreement obligates Purchaser, subject to the terms and conditions set forth
therein and to the satisfaction or waiver of the conditions set forth in
Conditions to the Offer below, to accept for payment and pay for, promptly
after the expiration of the Offer, all Shares validly tendered and not
withdrawn pursuant to the Offer and validly tendered in any subsequent offering
period. The date on which Shares are
first accepted for payment pursuant to the Offer is referred to as the Acceptance Date.
Subsequent Offering Period
.
Following expiration of the Offer,
Purchaser may, in its sole discretion, provide a subsequent offering period in
accordance with Rule 14d-11 of the Exchange Act.
Directors
and Officers
.
The Settlement Agreement provides that at or prior to the Acceptance
Date the Company shall obtain the resignation of each of its current directors
(other than Purchasers designees), effective as of the Acceptance Date, and
take all other action necessary to cause Purchasers designees to be elected or
appointed to the Companys board, effective as of the Acceptance Date.
Bylaw
Amendments
. The
Settlement Agreement provides that, at or prior to the Acceptance Date, the
Companys board will amend the Companys bylaws to remove Section 3.2 of
the bylaws (which relates to certain special director nomination
provisions). In addition, the Companys
board will amend Section 8.1 of the Companys bylaws to provide that,
during the Control Period (as defined in the Companys bylaws), bylaw
amendments by the Companys board may be effected by resolution of the board
and will not require the separate approval of a majority of the non-KPN
directors. These amendments are referred to as the Specified Bylaw Amendments.
Short-Form Merger
. The Settlement Agreement provides that if, as
a result of the consummation of the Offer, KPN and its affiliates own at least
90% of the outstanding Shares, the parties will take all necessary and
appropriate action to cause Merger Sub to be merged into the Company (the Merger)
as soon as practicable without a meeting of stockholders of the Company by way
of a short-form merger in accordance with Section 253 of the Delaware
General Corporation Law (the DGCL).
Stock
Options.
The
Settlement Agreement provides that at or immediately prior to the effective
time of the Merger, each option to purchase Shares that is outstanding, whether
or not vested or exercisable, will vest and be canceled, and the Company will
pay the holder of any such option at or promptly after the effective time of
the Merger an amount in cash equal to the excess, if any, of the Offer Price
over the applicable exercise price per Share of such option, multiplied by the
number of Shares issuable upon exercise of such option. The Settlement
Agreement also provides that, on the Acceptance Date, each unvested option to
purchase Shares that are held by a member of the Companys board will vest and
become exercisable, and will be treated, at the effective time of the Merger,
in the manner stated above.
Rule 14d-10 Matters
. The Settlement Agreement provides for certain
covenants on the part of the Company relating to Rule 14d-10 of the
Exchange Act and approvals that are to be made by the special committee with
respect to employment compensation, severance and other employee benefit plans
entered into prior to the Acceptance Date.
Other
Restrictions on Company Actions.
The
Settlement Agreement provides that the Company, the special committee, the
board of directors of the Company and the members of the special committee and
the board of directors of the Company shall not (a) adopt or propose to adopt any stockholder rights plan prior
to the termination of the Settlement Agreement or (b) commence (or
threaten to commence) any litigation seeking to or that would reasonably be
expected to impede, frustrate, prevent, enjoin, alter or materially delay the
Offer or any of the other transactions contemplated by the Settlement
Agreement, but only to the extent that
any such litigation is based primarily on facts known to the members of the
special committee as of the date of the Settlement Agreement.
Adverse Recommendation Change
.
The Settlement Agreement provides
that the special committee will (i) recommend that the Companys
stockholders tender their Shares in the Offer (the Special Committee
Recommendation) and (ii) not withhold, withdraw, qualify or modify in a
manner adverse to KPN or fail to make the Special Committee Recommendation or
publicly recommend or announce its intention to take any action or make any
statement inconsistent with the Special Committee Recommendation. However, the Settlement Agreement provides
that if the special committee determines in good faith (after considering the
advice of its outside legal and financial advisors) that continuing to make
this recommendation could reasonably be determined to be inconsistent with its
fiduciary duties under Delaware Law, then
3
the special
committee may make an adverse recommendation change, in which case the
obligations of the special committee under the immediately preceding sentence
will cease. The Settlement Agreement
further provides, however, that the special committee may not make an adverse
recommendation change until after at least 48 hours following KPNs receipt of
written notice from the Company advising KPN that the special committee intends
to make such an adverse recommendation change and the reasons therefor and the
special committee considers any modifications proposed by KPN during such 48-hour
period in order to eliminate the need for such adverse recommendation change.
Resignation of Ofer Gneezy and Gordon VanderBrug
. In connection with the Settlement Agreement,
at the request of Purchaser, Ofer Gneezy and Gordon VanderBrug each have delivered
to Purchaser letters of resignation agreeing that, effective immediately upon
the acceptance of Shares by Purchaser on the Acceptance Date, such person shall
resign in his capacity as a member of the Company Board and in all other
capacities in which he is employed by the Company. Such resignations will constitute good
reason under each of Mr. Gneezy and Dr. VanderBrugs employment
agreement.
Conditions to the Offer
.
Pursuant to the Settlement
Agreement, Purchaser is not required to accept for payment or pay for any
Shares pursuant to the Offer if:
(a) the Settlement Agreement shall have been
terminated in accordance with its terms; or
(b) at the expiration of the Offer;
(i)
the
Majority-of-the-Minority Condition shall not have been satisfied;
(ii)
any of the
other conditions to the Offer set forth in the Schedule TO (as amended by
Amendment Nos. 1 through 7 thereto) shall not have been satisfied;
(iii)
the special
committee shall have withheld, withdrawn, qualified or modified in a manner
adverse to KPN or failed to make the Special Committee Recommendation or
publicly recommended or announced its intention to take any action or make any
statement inconsistent with the Special Committee Recommendation; and
(iv)
the Company
shall not have (A) taken the actions necessary to cause the Specified
Bylaw Amendments to become effective, (B) delivered to Purchaser the
director resignations contemplated by the Settlement Agreement, which
resignations shall be valid, binding and effective or (C) otherwise
performed in all material respects the obligations, and complied in all
material respects with the agreements and covenants, required to be performed
by, or complied with by, it as described under Directors and Officers, Bylaw
Amendments and Rule 14d-10 Matters above.
Subject to the terms and
conditions of the Settlement Agreement, the foregoing conditions to the Offer
are for the sole benefit of KPN, Purchaser and Merger Sub and, subject to the
terms and conditions of the Settlement Agreement and the applicable rules and
regulations of the SEC, may be waived by KPN, Purchaser or Merger Sub, in whole
or in part, at any time;
provided
that Majority-of-the-Minority Condition is nonwaivable.
Termination
.
The Settlement Agreement may be
terminated and the Offer may be abandoned:
·
at any time prior to the
effective time of the Merger by mutual written agreement of the
Company (provided that such termination has been approved by the special
committee) and KPN; or
·
by either the Company
(provided that such termination has been approved by the special committee) or
KPN, if prior to the Acceptance Date:
·
the Acceptance
Date has not occurred on or before January 8, 2010 (except that this right
to terminate the Settlement Agreement will not be available to any party whose
breach of any provision of the Settlement Agreement results in the failure of
the Offer to be consummated by such time),
·
there is a law
or final non-appealable judgment, injunction, order or decree of any
governmental authority with competent jurisdiction restraining, prohibiting or
otherwise making illegal the consummation of the Offer, or
·
by KPN prior to the
Acceptance Date if, prior to the Acceptance Date, the special committee
has made an adverse recommendation change as described under Adverse
Recommendation Change above that remains in effect; or
4
·
by the Company if
Purchaser shall have terminated the Offer (other than in connection with a
valid termination of the Settlement Agreement) or Purchaser shall fail to
accept for payment and pay for Shares validly tendered and not withdrawn in the
Offer at the expiration thereof.
Effect of Termination
.
If the Settlement Agreement is
terminated in accordance with its terms, the Settlement Agreement will become
void and of no effect with no liability on the part of any party (or any
stockholder, director, officer, employee, agent or advisor of such party) to
the other party;
provided
that if
such termination results from a material breach of the Settlement Agreement,
such party will be fully liable for any and all liabilities and damages
incurred or suffered by the other party as a result of such breach. The termination of the Settlement Agreement
will not, however, terminate the sections of the Settlement Agreement relating
to the dismissal of the iBasis Delaware Action and iBasis New York Action, the
parties mutual releases, the termination of the Rights Agreement or certain of
the Companys covenants under Other Restrictions on Company Actions above.
Expenses
.
All costs and expenses incurred in
connection with the Settlement Agreement will be paid by the party incurring
such cost or expense.
Amendments or Waivers
. Any provision
of the Settlement Agreement may be amended or waived prior to the effective
time of the Merger if, but only if, such amendment or waiver is in writing and
is signed, in the case of an amendment, by each party to the Settlement
Agreement or, in the case of a waiver, by each party against whom the waiver is
to be effective;
provided
that
any such amendment or waiver by the Company will require the approval of the
special committee.
Item
1.02
Termination of a Material Definitive Agreement.
As disclosed in
the Companys Current Report on Form 8-K filed on July 30, 2009, the
Company entered into a Rights Agreement (the Rights Agreement), dated as of July 30,
2009, by and between the Company and Computershare Trust Company, N.A., as
rights agent (the Rights Agent).
Pursuant to the terms of the Settlement Agreement described in Item 1.01
above, the Company and the special committee to the Companys Board of
Directors have agreed to take all action necessary to terminate the Rights
Agreement by entering into an amendment to the Rights Agreement within four
business days following the execution and delivery of the Settlement Agreement.
Item
3.03
Material Modification to Rights of Security Holders.
See the
description set forth under Item 1.02 - Termination of a Material Definitive
Agreement, which is incorporated by reference into this Item 3.03.
Item
5.02
Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
(b)
On November 23, 2009, Ofer Gneezy, the Companys
President and Chief Executive Officer, and Gordon J. VanderBrug, the Companys
Executive Vice President, executed letters of resignation for good reason
with the Company and Purchaser (the Resignation Letters). The Resignation Letters are subject to, and
effective only upon, the consummation of the Offer (the Termination Date). The conditions for consummation of the Offer
are described in Item 1.01 above.
In addition, on November 23,
2009, pursuant to the Settlement Agreement, certain of the Companys directors,
including Robert H. Brumley, Charles Corfield and W. Frank King, will resign
from the Companys Board of Directors subject to, and effective only upon, the
consummation of the Offer.
(e)
As disclosed in the Companys Current Report on Form 8-K
filed on May 14, 2009, the Company entered into severance and
change-in-control agreements with its executive officers, including Ofer Gneezy
and Gordon J. VanderBrug, on May 11, 2009 (the Agreements). The Resignation Letters confirm that the severance benefits set forth in the
Agreements will be paid upon the resignation of Mr. Gneezy and Mr. VanderBrug
if the Offer is consummated. The
Agreements provide that, in the event of a termination of employment by the
Company without cause or by the executive for good reason, as such terms
are defined in the agreement, the executive will be entitled to payment of a
pro-rata annual bonus up to the date of termination, the continuation of base
salary for a period of 24 months following the termination date, payment of an
amount equal to two times the executives full target annual bonus for the year
in which the termination occurs, the right to exercise any stock options
granted under the applicable stock plan for the shorter of the period provided
5
under the applicable
stock plan or 90 days following the termination date to the extent that such
stock options are vested and exercisable during such period, payment of restricted
stock that would have vested within 90 days following termination and the
continued payment of the employer-paid premiums for medical, dental and other
health benefits for the 24 month severance period. In exchange for the
severance and change in control benefits, the agreements also contain
non-competition and non-solicitation provisions by which the executives have
agreed to be bound during their respective severance periods and require the
executives to enter into general releases of all claims against the Company,
its affiliates, agents and employees in order to receive the termination
benefits. In addition, the Resignation
Letters amend the Agreements to provide (i) the payment of the pro rata
annual bonus for 2009, which may be the full amount of such bonus if the
termination occurs in 2010, and (ii) that any stock options owned by Mr. Gneezy
and Dr. VanderBrug, which otherwise would have remained unvested, will
vest fully as of the Termination Date.
The consummation of the Offer and the Merger will not constitute a
change in control for purposes of the Agreements.
Item
8.01
Other Events.
On November 23,
2009, the Company issued a joint press release with KPN announcing the material
terms of the Settlement Agreement, the description of which set forth under Item
1.01 - Entry into a Material Definitive Agreement and is incorporated by
reference into this Item 8.01. In
addition, a copy of the press release is attached to this Current Report on Form 8-K
as Exhibit 99.1 and is incorporated herein by reference.
Item
9.01
Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
Number
|
|
Description
|
10.1
|
|
Settlement Agreement,
dated November 23, 2009, among the Company, KPN B.V., Koninklijke
KPN N.V. and Celtic ICS Inc.
|
|
|
|
10.2
|
|
Resignation Letter of
Ofer Gneezy, dated November 23, 2009.
|
|
|
|
10.3
|
|
Resignation Letter of
Gordon J. VanderBrug, Ph.D., dated November 23, 2009.
|
|
|
|
99.1
|
|
Press Release, dated
November 23, 2009.
|
6
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
iBASIS,
INC.
|
|
|
|
|
By:
|
/s/ Mark S. Flynn
|
|
Name:
|
Mark S. Flynn
|
|
Title:
|
Chief Legal Officer and
Corporate Secretary
|
Date: November 23,
2009
7
EXHIBIT INDEX
Exhibit
Number
|
|
Description
|
10.1
|
|
Settlement Agreement,
dated November 23, 2009, among the Company, KPN B.V., Koninklijke
KPN N.V. and Celtic ICS Inc.
|
|
|
|
10.2
|
|
Resignation Letter of
Ofer Gneezy, dated November 23, 2009.
|
|
|
|
10.3
|
|
Resignation Letter of
Gordon J. VanderBrug, Ph.D., dated November 23, 2009.
|
|
|
|
99.1
|
|
Press Release, dated
November 23, 2009.
|
8
Ibasis (MM) (NASDAQ:IBAS)
Historical Stock Chart
From Dec 2024 to Jan 2025
Ibasis (MM) (NASDAQ:IBAS)
Historical Stock Chart
From Jan 2024 to Jan 2025